Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 15 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
13 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
BioRICS from Leuven, company number BE0880194826, closed financial year 2025 with a result of € -194,737 after tax. For that financial year BioRICS recorded a gross margin of € 369,639 and equity of € -104,780. Compared with financial year 2024, the result moved from € -208,082 to € -194,737. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 7, 2026.
€ -104,780
▼ € 194,737 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -194,737
▲ 6 % less loss than in 2024
Profit after tax over the fiscal year.
€ 5,230
▲ € 4,432 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1.5 million.
People and assets in 2025
2.8
▲ 0.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 248,084
▼ 25% vs 2024
€ 88,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 731,099
▼ 1% vs 2024
€ 692,400 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.
€ 259,530
▲ 21% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 91,323
▲ 125% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -423,288 | € 32,369 | € 422,335 | € 369,639 | ▼ 12% |
| Profit after taxes | € -765,433 | € -412,754 | € -208,082 | € -194,737 | ▲ € 13,345 |
| Equity | € 710,793 | € 298,040 | € 89,958 | € -104,780 | ▼ € 194,737 |
| Total debts | € 796,060 | € 1,401,143 | € 2,217,491 | € 2,287,419 | ▲ 3% |
| Cash | € 547 | € 21,158 | € 798 | € 5,230 | ▲ € 4,432 |
| Retained profit | € -639,207 | € -1,051,960 | € -1,260,042 | € -1,454,780 | ▼ € 194,737 |
| Bank debt | € 79,702 | € 71,823 | € 739,589 | € 731,099 | ▼ 1% |
| Balance sheet total | € 1,506,853 | € 1,699,183 | € 2,307,448 | € 2,182,640 | ▼ 5% |
| Employees (FTE) | 3.8 | 2.7 | 2.4 | 2.8 | ▲ 0.4 |
By gross margin, BioRICS ranks 7th of 21 companies with main activity “Overige advisering in verband met programmatuur en levering van programmatuur” in Leuven that publish figures (fiscal year 2025).
Key figures of BioRICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about BioRICS the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to BioRICS?
What happened at BioRICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Daniel Berckmans stepped down as director. NBB
- Ann Goeman stepped down as director. NBB
- Mastermind Advisory Services stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 194,737. filed late Source: NBB ↗
- Ann Goeman became a director. NBB
- Capital increase published in the Gazette. Source: Staatsblad ↗
- Daniel Berckmans became a director. NBB
- Mastermind Advisory Services became a director. NBB
In short
From € 765,433 loss in 2022 to € 194,737 loss in 2025.
On average € 132,000 of value added per employee in 2025.
Management
The stake of SENSINNOVAT comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
BioRICSThe shares are held by SENSINNOVAT (23.8%). It owns BioRICS INC. itself.
Directors
According to the 2025 annual accounts
since 2021 · until 2027
Ann Goeman
Director
since 2024 · until 2027
Director · represented by Axel Heinemann
Also active at: European Spatial Biology Center
since 2021 · until 2027
Shareholders
23.8%
Participations
BioRICS INC.
Establishments
Establishment units
Physical locations of this company
Technologielaan 3
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 13 companies are registered at this address.
All companies at this address →ES BROADCAST MEDIA
€ 411,233 gross margin · 2026
CUE - GRAPHICS
€ 12,725 gross margin · 2025
DELCOMP
€ 122,487 gross margin · 2025
CAPVIDIA
€ 387,041 gross margin · 2025
ES INVESTMENT
€ 123,140 gross margin · 2025
+8 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Leuven
Same main activity (Overige advisering in verband met programmatuur en levering van programmatuur), 25 active companies in Leuven, largest first.
€ 353.6 million revenue · 2025
€ 64.8 million revenue · 2025
€ 15.6 million revenue · 2024
PROJECT ENGINEERING AND CONTRACTING
€ 14.6 million revenue · 2025
€ 13.6 million revenue · 2025
€ 3.2 million gross margin · 2025
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Domain
Domain
biorics.com
Registered
2003-01-26
Registrar
Bluehost Inc.
Expires
2027-01-26
Website info
Features
Security
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Capital increase
Source: Deed ↗- BIOSYSTEMS CONSULT(inbrenger schuldvordering in rekening-courant) 4.8%
- CLARITYADVISORY(inbrenger schuldvordering in rekening-courant) 4.8%
Incorporation
Source: Deed ↗- Verplaetse Alex René Julien Remı(oprichter) 47.4%
- Goddaert Jan Amaat Jozefina Renatus(oprichter) 31.6%
- Berckmans Daniel Albert(oprichter) 21.1%
Details
- Company number
- 0880.194.826
- VAT number
- BE 0880.194.826
- Registered office
- Technologielaan 3, 3001 Leuven
- Names & denominations
- BioRICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 10 March 2006
- Peppol
- Active · Active since 16 Dec 2025
- Contact
- biorics.com
- Activities · NACE
Overige advisering in verband met programmatuur en levering van programmatuur
Ontwerpen van computerprogramma’s
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Ontwerpen en programmeren van computerprogramma's
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
+8